Skip to main content
Erschienen in: Clinical & Experimental Metastasis 2/2015

01.02.2015 | Research Paper

HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations

verfasst von: F. Darío Cuello-Carrión, Jorge E. Shortrede, Daiana Alvarez-Olmedo, Niubys Cayado-Gutiérrez, Gisela N. Castro, Felipe C. M. Zoppino, Martín Guerrero, Estefania Martinis, Rodolfo Wuilloud, Nidia N. Gómez, Verónica Biaggio, Javier Orozco, Francisco E. Gago, Leonardo A. Ciocca, Mariel A. Fanelli, Daniel R. Ciocca

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

In human breast cancer, β-catenin localization has been related with disease prognosis. Since HER2-positive patients are an important subgroup, and that in breast cancer cells a direct interaction of β-catenin/HER2 has been reported, in the present study we have explored whether β-catenin location is related with the disease survival. The study was performed in a tumor bank from patients (n = 140) that did not receive specific anti-HER2 therapy. The proteins were detected by immunohistochemistry in serial sections, 47 (33.5 %) patients were HER2-positive with a long follow-up. HER2-positive patients that displayed β-catenin at the plasma membrane (completely surrounding the tumour cells) showed a significant better disease-free survival and overall survival than the patients showing the protein on other locations. Then we explored the dynamics of the co-expression of β-catenin and HER2 in human MCF-7 and SKBR3 cells exposed to different stressful situations. In untreated conditions MCF-7 and SKBR3 cells showed very different β-catenin localization. In MCF-7 cells, cadmium administration caused a striking change in β-catenin localization driving it from plasma membrane to cytoplasmic and perinuclear areas and HER2 showed a similar localization patterns. The changes induced by cadmium were compared with heat shock, H2O2 and tamoxifen treatments. In conclusion, this study shows the dynamical associations of HER2 and β-catenin and their changes in subcellular localizations driven by stressful situations. In addition, we report for the first time the correlation between plasma membrane associated β-catenin in HER2-positive breast cancer and survival outcome, and the importance of the protein localization in breast cancer samples.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fanelli MA et al (2008) P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 13(2):207–220PubMedCentralPubMedCrossRef Fanelli MA et al (2008) P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 13(2):207–220PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Rosenbluh J, Wang X, Hahn WC (2014) Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol Sci 35(2):103–109PubMedCentralPubMed Rosenbluh J, Wang X, Hahn WC (2014) Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol Sci 35(2):103–109PubMedCentralPubMed
4.
Zurück zum Zitat Lopez-Knowles E et al (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomark Prev 19(1):301–309CrossRef Lopez-Knowles E et al (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomark Prev 19(1):301–309CrossRef
5.
Zurück zum Zitat Li S, Sun Y, Li L (2014) The expression of beta-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol 35(8):7693–7698PubMedCrossRef Li S, Sun Y, Li L (2014) The expression of beta-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol 35(8):7693–7698PubMedCrossRef
6.
Zurück zum Zitat Kanai Y et al (1995) c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 208(3):1067–1072PubMedCrossRef Kanai Y et al (1995) c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 208(3):1067–1072PubMedCrossRef
7.
Zurück zum Zitat Wang K et al (2007) Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 17(1):89–96PubMed Wang K et al (2007) Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 17(1):89–96PubMed
8.
Zurück zum Zitat Shibata T et al (1996) Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13(5):883–889PubMed Shibata T et al (1996) Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13(5):883–889PubMed
9.
10.
Zurück zum Zitat Schroeder JA et al (2002) ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277(25):22692–22698PubMedCrossRef Schroeder JA et al (2002) ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277(25):22692–22698PubMedCrossRef
12.
Zurück zum Zitat Ciocca DR et al (2012) Absence of caveolin-1 alters heat shock protein expression in spontaneous mammary tumors driven by Her-2/neu expression. Histochem Cell Biol 137(2):187–194PubMedCrossRef Ciocca DR et al (2012) Absence of caveolin-1 alters heat shock protein expression in spontaneous mammary tumors driven by Her-2/neu expression. Histochem Cell Biol 137(2):187–194PubMedCrossRef
13.
Zurück zum Zitat Cuello-Carrion FD et al (2013) In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not beta-catenin expression. Cell Stress Chaperones 18(5):559–567PubMedCentralPubMedCrossRef Cuello-Carrion FD et al (2013) In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not beta-catenin expression. Cell Stress Chaperones 18(5):559–567PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Gago FE, Fanelli MA, Ciocca DR (2006) Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 98(1):36–40PubMedCrossRef Gago FE, Fanelli MA, Ciocca DR (2006) Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 98(1):36–40PubMedCrossRef
15.
Zurück zum Zitat Parker BS et al (2008) Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 214(3):337–346PubMedCrossRef Parker BS et al (2008) Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 214(3):337–346PubMedCrossRef
16.
Zurück zum Zitat Straif K et al (2009) A review of human carcinogens–part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10(5):453–454PubMedCrossRef Straif K et al (2009) A review of human carcinogens–part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10(5):453–454PubMedCrossRef
18.
Zurück zum Zitat Gallagher CM, Chen JJ, Kovach JS (2010) Environmental cadmium and breast cancer risk. Aging (Albany NY) 2(11):804–814 Gallagher CM, Chen JJ, Kovach JS (2010) Environmental cadmium and breast cancer risk. Aging (Albany NY) 2(11):804–814
19.
Zurück zum Zitat McElroy JA et al (2006) Cadmium exposure and breast cancer risk. J Natl Cancer Inst 98(12):869–873PubMedCrossRef McElroy JA et al (2006) Cadmium exposure and breast cancer risk. J Natl Cancer Inst 98(12):869–873PubMedCrossRef
20.
Zurück zum Zitat Benbrahim-Tallaa L et al (2009) Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect 117(12):1847–1852PubMedCentralPubMedCrossRef Benbrahim-Tallaa L et al (2009) Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect 117(12):1847–1852PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Pasha Q et al (2008) Comparative evaluation of trace metal distribution and correlation in human malignant and benign breast tissues. Biol Trace Elem Res 125(1):30–40PubMedCrossRef Pasha Q et al (2008) Comparative evaluation of trace metal distribution and correlation in human malignant and benign breast tissues. Biol Trace Elem Res 125(1):30–40PubMedCrossRef
22.
Zurück zum Zitat Gutiérrez JG et al (2008) Interleukin-12p40 contributes to protection against lung injury after oral Yersinia enterocolitica infection. Inflamm Res 57(11):504–511PubMedCrossRef Gutiérrez JG et al (2008) Interleukin-12p40 contributes to protection against lung injury after oral Yersinia enterocolitica infection. Inflamm Res 57(11):504–511PubMedCrossRef
23.
Zurück zum Zitat Liu Y et al (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69(2):581–593PubMedCrossRef Liu Y et al (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69(2):581–593PubMedCrossRef
24.
Zurück zum Zitat Cuello-Carrion FD, Ciocca DR (1999) Improved detection of apoptotic cells using a modified in situ TUNEL technique. J Histochem Cytochem 47(6):837–839PubMedCrossRef Cuello-Carrion FD, Ciocca DR (1999) Improved detection of apoptotic cells using a modified in situ TUNEL technique. J Histochem Cytochem 47(6):837–839PubMedCrossRef
25.
Zurück zum Zitat Dimri GP et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363–9367PubMedCentralPubMedCrossRef Dimri GP et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363–9367PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Molina R et al (1992) Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12(6B):1965–1971PubMed Molina R et al (1992) Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12(6B):1965–1971PubMed
27.
Zurück zum Zitat Ciocca DR et al (1992) Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84(16):1279–1282PubMedCrossRef Ciocca DR et al (1992) Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84(16):1279–1282PubMedCrossRef
28.
Zurück zum Zitat Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013PubMedCrossRef Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013PubMedCrossRef
29.
Zurück zum Zitat Allred DC, O’Connell P, Fuqua SA, Osborne CK (1994) Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 32(1):13–18PubMedCrossRef Allred DC, O’Connell P, Fuqua SA, Osborne CK (1994) Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 32(1):13–18PubMedCrossRef
30.
Zurück zum Zitat Suzuki H et al (2008) Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 28(3B):1821–1830PubMed Suzuki H et al (2008) Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 28(3B):1821–1830PubMed
31.
Zurück zum Zitat Schade B et al (2013) β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res 73(14):4474–4487PubMedCrossRef Schade B et al (2013) β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res 73(14):4474–4487PubMedCrossRef
32.
Zurück zum Zitat Cordo Russo RI et al (2014) Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene 2014 Sep 1;0. doi:10.1038/onc.2014.272. [Epub ahead of print] Cordo Russo RI et al (2014) Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.  Oncogene 2014 Sep 1;0. doi:10.​1038/​onc.​2014.​272. [Epub ahead of print]
33.
Zurück zum Zitat Hsu MC, Chang HC, Hung WC (2007) HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer 14(3):655–667PubMedCrossRef Hsu MC, Chang HC, Hung WC (2007) HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer 14(3):655–667PubMedCrossRef
35.
Zurück zum Zitat Khalil S et al (2012) Activation status of Wnt/ss-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS ONE 7(3):e33421PubMedCentralPubMedCrossRef Khalil S et al (2012) Activation status of Wnt/ss-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS ONE 7(3):e33421PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Khramtsov AI et al (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176(6):2911–2920PubMedCentralPubMedCrossRef Khramtsov AI et al (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176(6):2911–2920PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Pavlakis K et al (2014) p85 Protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with Trastuzumab. Pathol Oncol Res 2014 Aug 8. doi:10.1007/s12253-014-9818-2. [Epub ahead of print] Pavlakis K et al (2014) p85 Protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with Trastuzumab. Pathol Oncol Res 2014 Aug 8. doi:10.​1007/​s12253-014-9818-2. [Epub ahead of print]
38.
Zurück zum Zitat Subik K et al (2010) The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer: Basic Clin Res 4:35–41 Subik K et al (2010) The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer: Basic Clin Res 4:35–41
39.
Zurück zum Zitat Park MH et al (2012) Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun 419(3):543–549PubMedCrossRef Park MH et al (2012) Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun 419(3):543–549PubMedCrossRef
40.
Zurück zum Zitat Arias-Romero LE et al (2010) A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 29(43):5839–5849PubMedCentralPubMedCrossRef Arias-Romero LE et al (2010) A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 29(43):5839–5849PubMedCentralPubMedCrossRef
41.
Metadaten
Titel
HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations
verfasst von
F. Darío Cuello-Carrión
Jorge E. Shortrede
Daiana Alvarez-Olmedo
Niubys Cayado-Gutiérrez
Gisela N. Castro
Felipe C. M. Zoppino
Martín Guerrero
Estefania Martinis
Rodolfo Wuilloud
Nidia N. Gómez
Verónica Biaggio
Javier Orozco
Francisco E. Gago
Leonardo A. Ciocca
Mariel A. Fanelli
Daniel R. Ciocca
Publikationsdatum
01.02.2015
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 2/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-015-9694-5

Weitere Artikel der Ausgabe 2/2015

Clinical & Experimental Metastasis 2/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.